Friday 6 November 2026 Export IONS’s income statement to Excel — free account

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue: −40.7%
EPS: −188.5%
Free cash flow: +299.3%
Total debt: +116.0%

Quarter to June 2026, against a year earlier

Insider buying

39.48 0.68 +1.75%

Follow IONS

Alert me

Market cap: $6.5B
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: —
F-score: 4/9
Altman Z: 2.12
Beneish M: −3.13
Dividend safety: n/a

Overview Business Profile Segments Valuation Filings

Ionis Pharmaceuticals, Inc. (IONS) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Collaborative Agreement Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
SPINRAZA Royalties	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
TRYNGOLZA Sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
WAINUA Royalties	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
WAINUA Joint Development Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Royalties	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
DAWNZERA Sales	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Commercial Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Commercial Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Product Sales, Net	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Research and Development Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Royalty Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Ionis Pharmaceuticals, Inc. (IONS) revenue by segment, product and region

Stockrow Weekly